A POSTDOCTORAL POSITION is available in the Comprehensive Cancer Center of the University of California San Francisco (UCSF) to identify drugs and drug combinations in novel model systems that will be of use for patient-specific (personalized) medicine. Model systems in use include patient-derived xenografts (PDX) and 3-dimensional cancer spheroids and 3-D bioprinted human cancers derived from patient tumors. Primary liver tumors (hepatocellular carcinoma, cholangiocarcinoma), and liver metastases (pancreatic neuroendocrine tumors, and colorectal cancer) from freshly resected patient tumors are available for interrogation. The research is a collaborative effort among faculty in the Cancer Center and the Department of Surgery, which will encourage the successful candidate to identify therapeutics that target phenotypes common to these liver neoplasms or to use medium to high throughput screens with drugs or drug combinations using robotics. The goal of these studies is to identify targeted drugs that can be rapidly translated to the assistance of our patients. Novel drugs developed at UCSF that target chokepoints in growth factor signaling pathways are also available for these studies.
Qualifications: Candidates must have a PhD, MD, MD/PhD or equivalent in molecular biology, biochemistry, immunology, structural biology or a related field with a demonstrated track record of productive research. A strong background in molecular and cellular biology techniques is essential. The ideal candidate will also have good spoken and written communication skills, and a strong interest in translational and clinical research.
Submit a cover letter together with a CV and the names and Email contact information of 3 references to Dr. Robert S. Warren (Robert.Warren@ucsf.edu) or Dr. David Donner (email@example.com) at the University of California San Francisco. UCSF is an equal opportunity employer and we encourage applications from women and minorities.